“…Thirteen studies (14%) reported patient outcomes ( 18 , 19 , 22 , 30 , 60 , 70 , 71 , 82 , 84 , 90 , 93 , 103 , 115 ), such as disease progression or incidence of complications. Seven studies (7%) reported costs as the outcome ( 34 , 52 , 76 , 78 , 92 , 99 , 105 ), such as cost-effectiveness of a screening program for certain patient subgroups. Two studies investigated the response to test results ( 51 , 72 ), i.e.…”